DeBattista Charles, DeBattista Kristina
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
Curr Drug Saf. 2010 Jul 2;5(3):263-6. doi: 10.2174/157488610791698325.
Second generation antipsychotics (SGAs) are increasingly employed in the treatment of depression. Adjunctive aripiprizole and olanzapine/ fluoxetine combination (OFC) have been approved in the US in the treatment of depression. Quetiapine also appears to be poised for an FDA approval as an adjunctive treatment for resistant depression. Historically, first generation antipsychotics were thought to carry an enhanced risk of certain side effects in the treatment of mood disorders, including an enhanced risk of extrapyramidal symptoms (EPS). The second generation antipsychotics are also known to be associated with a variety of metabolic side effects. The use of SGA in a depressed population may pose risks that differ from use in other conditions such as bipolar disorder and schizophrenia. In this paper, the risk of extrapyramidal and metabolic side effects is reviewed in depressed patients treated with second generation antipsychotics.
第二代抗精神病药物（SGAs）越来越多地用于治疗抑郁症。辅助使用阿立哌唑和奥氮平/氟西汀组合（OFC）在美国已被批准用于治疗抑郁症。喹硫平似乎也即将获得美国食品药品监督管理局（FDA）批准，作为难治性抑郁症的辅助治疗药物。从历史上看，第一代抗精神病药物被认为在治疗情绪障碍时会增加某些副作用的风险，包括锥体外系症状（EPS）风险增加。已知第二代抗精神病药物也与多种代谢副作用有关。在抑郁症患者中使用SGAs可能带来与双相情感障碍和精神分裂症等其他病症使用时不同的风险。本文回顾了使用第二代抗精神病药物治疗的抑郁症患者发生锥体外系和代谢副作用的风险。
